Medical - Diagnostics & Research
Compare Stocks
2 / 10Stock Comparison
MTD vs TMO
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Diagnostics & Research
MTD vs TMO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Diagnostics & Research | Medical - Diagnostics & Research |
| Market Cap | $27.00B | $175.76B |
| Revenue (TTM) | $4.03B | $45.20B |
| Net Income (TTM) | $869M | $6.86B |
| Gross Margin | 57.5% | 39.4% |
| Operating Margin | 27.8% | 17.8% |
| Forward P/E | 28.6x | 19.0x |
| Total Debt | $2.34B | $40.85B |
| Cash & Equiv. | $67M | $9.86B |
MTD vs TMO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Mettler-Toledo Inte… (MTD) | 100 | 167.1 | +67.1% |
| Thermo Fisher Scien… (TMO) | 100 | 135.4 | +35.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: MTD vs TMO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
MTD carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 4.0%, EPS growth 3.7%, 3Y rev CAGR 0.9%
- 271.8% 10Y total return vs TMO's 229.1%
- PEG 2.57 vs TMO's 9.02
TMO is the clearest fit if your priority is income & stability and sleep-well-at-night.
- Dividend streak 8 yrs, beta 1.10, yield 0.4%
- Lower volatility, beta 1.10, Low D/E 76.3%, current ratio 1.89x
- Beta 1.10, yield 0.4%, current ratio 1.89x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 4.0% revenue growth vs TMO's 3.9% | |
| Value | Lower P/E (19.0x vs 28.6x) | |
| Quality / Margins | 21.6% margin vs TMO's 15.2% | |
| Stability / Safety | Beta 1.10 vs MTD's 1.31 | |
| Dividends | 0.4% yield; 8-year raise streak; the other pay no meaningful dividend | |
| Momentum (1Y) | +24.9% vs TMO's +16.6% | |
| Efficiency (ROA) | 25.1% ROA vs TMO's 6.4%, ROIC 40.0% vs 7.5% |
MTD vs TMO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
MTD vs TMO — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
MTD leads this category, winning 6 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
TMO is the larger business by revenue, generating $45.2B annually — 11.2x MTD's $4.0B. MTD is the more profitable business, keeping 21.6% of every revenue dollar as net income compared to TMO's 15.2%.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $4.0B | $45.2B |
| EBITDAEarnings before interest/tax | $1.2B | $10.5B |
| Net IncomeAfter-tax profit | $869M | $6.9B |
| Free Cash FlowCash after capex | $849M | $6.7B |
| Gross MarginGross profit ÷ Revenue | +57.5% | +39.4% |
| Operating MarginEBIT ÷ Revenue | +27.8% | +17.8% |
| Net MarginNet income ÷ Revenue | +21.6% | +15.2% |
| FCF MarginFCF ÷ Revenue | +21.1% | +14.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | +8.1% | +6.2% |
| EPS Growth (YoY)Latest quarter vs prior year | +17.2% | +11.3% |
Valuation Metrics
TMO leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
At 26.7x trailing earnings, TMO trades at a 15% valuation discount to MTD's 31.5x P/E. Adjusting for growth (PEG ratio), MTD offers better value at 2.84x vs TMO's 12.62x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | ||
|---|---|---|
| Market CapShares × price | $27.0B | $175.8B |
| Enterprise ValueMkt cap + debt − cash | $29.3B | $206.8B |
| Trailing P/EPrice ÷ TTM EPS | 31.50x | 26.66x |
| Forward P/EPrice ÷ next-FY EPS est. | 28.56x | 19.04x |
| PEG RatioP/E ÷ EPS growth rate | 2.84x | 12.62x |
| EV / EBITDAEnterprise value multiple | 23.53x | 18.99x |
| Price / SalesMarket cap ÷ Revenue | 6.70x | 3.94x |
| Price / BookPrice ÷ Book value/share | — | 3.33x |
| Price / FCFMarket cap ÷ FCF | 31.81x | 27.93x |
Profitability & Efficiency
MTD leads this category, winning 6 of 6 comparable metrics.
Profitability & Efficiency
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | — | +13.2% |
| ROA (TTM)Return on assets | +25.1% | +6.4% |
| ROICReturn on invested capital | +40.0% | +7.5% |
| ROCEReturn on capital employed | +48.8% | +9.1% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 6 |
| Debt / EquityFinancial leverage | — | 0.76x |
| Net DebtTotal debt minus cash | $2.3B | $31.0B |
| Cash & Equiv.Liquid assets | $67M | $9.9B |
| Total DebtShort + long-term debt | $2.3B | $40.9B |
| Interest CoverageEBIT ÷ Interest expense | 16.28x | 5.89x |
Total Returns (Dividends Reinvested)
MTD leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MTD five years ago would be worth $10,228 today (with dividends reinvested), compared to $10,211 for TMO. Over the past 12 months, MTD leads with a +24.9% total return vs TMO's +16.6%. The 3-year compound annual growth rate (CAGR) favors MTD at -1.6% vs TMO's -4.2% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -5.9% | -20.1% |
| 1-Year ReturnPast 12 months | +24.9% | +16.6% |
| 3-Year ReturnCumulative with dividends | -4.7% | -11.9% |
| 5-Year ReturnCumulative with dividends | +2.3% | +2.1% |
| 10-Year ReturnCumulative with dividends | +271.8% | +229.1% |
| CAGR (3Y)Annualised 3-year return | -1.6% | -4.2% |
Risk & Volatility
Evenly matched — MTD and TMO each lead in 1 of 2 comparable metrics.
Risk & Volatility
TMO is the less volatile stock with a 1.10 beta — it tends to amplify market swings less than MTD's 1.31 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. MTD currently trades 87.1% from its 52-week high vs TMO's 73.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.31x | 1.10x |
| 52-Week HighHighest price in past year | $1525.17 | $643.99 |
| 52-Week LowLowest price in past year | $1052.05 | $385.46 |
| % of 52W HighCurrent price vs 52-week peak | +87.1% | +73.4% |
| RSI (14)Momentum oscillator 0–100 | 53.3 | 39.8 |
| Avg Volume (50D)Average daily shares traded | 147K | 1.9M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates MTD as "Hold" and TMO as "Buy". Consensus price targets imply 38.4% upside for TMO (target: $655) vs 12.2% for MTD (target: $1491). TMO is the only dividend payer here at 0.36% yield — a key consideration for income-focused portfolios.
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy |
| Price TargetConsensus 12-month target | $1490.83 | $654.67 |
| # AnalystsCovering analysts | 19 | 42 |
| Dividend YieldAnnual dividend ÷ price | — | +0.4% |
| Dividend StreakConsecutive years of raises | — | 8 |
| Dividend / ShareAnnual DPS | — | $1.69 |
| Buyback YieldShare repurchases ÷ mkt cap | +3.0% | +1.7% |
MTD leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). TMO leads in 1 (Valuation Metrics). 1 tied.
MTD vs TMO: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is MTD or TMO a better buy right now?
For growth investors, Mettler-Toledo International Inc.
(MTD) is the stronger pick with 4. 0% revenue growth year-over-year, versus 3. 9% for Thermo Fisher Scientific Inc. (TMO). Thermo Fisher Scientific Inc. (TMO) offers the better valuation at 26. 7x trailing P/E (19. 0x forward), making it the more compelling value choice. Analysts rate Thermo Fisher Scientific Inc. (TMO) a "Buy" — based on 42 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — MTD or TMO?
On trailing P/E, Thermo Fisher Scientific Inc.
(TMO) is the cheapest at 26. 7x versus Mettler-Toledo International Inc. at 31. 5x. On forward P/E, Thermo Fisher Scientific Inc. is actually cheaper at 19. 0x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Mettler-Toledo International Inc. wins at 2. 57x versus Thermo Fisher Scientific Inc. 's 9. 02x.
03Which is the better long-term investment — MTD or TMO?
Over the past 5 years, Mettler-Toledo International Inc.
(MTD) delivered a total return of +2. 3%, compared to +2. 1% for Thermo Fisher Scientific Inc. (TMO). Over 10 years, the gap is even starker: MTD returned +271. 8% versus TMO's +229. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — MTD or TMO?
By beta (market sensitivity over 5 years), Thermo Fisher Scientific Inc.
(TMO) is the lower-risk stock at 1. 10β versus Mettler-Toledo International Inc. 's 1. 31β — meaning MTD is approximately 19% more volatile than TMO relative to the S&P 500.
05Which is growing faster — MTD or TMO?
By revenue growth (latest reported year), Mettler-Toledo International Inc.
(MTD) is pulling ahead at 4. 0% versus 3. 9% for Thermo Fisher Scientific Inc. (TMO). On earnings-per-share growth, the picture is similar: Thermo Fisher Scientific Inc. grew EPS 7. 3% year-over-year, compared to 3. 7% for Mettler-Toledo International Inc.. Over a 3-year CAGR, MTD leads at 0. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — MTD or TMO?
Mettler-Toledo International Inc.
(MTD) is the more profitable company, earning 21. 6% net margin versus 15. 1% for Thermo Fisher Scientific Inc. — meaning it keeps 21. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MTD leads at 27. 8% versus 18. 2% for TMO. At the gross margin level — before operating expenses — MTD leads at 57. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is MTD or TMO more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Mettler-Toledo International Inc. (MTD) is the more undervalued stock at a PEG of 2. 57x versus Thermo Fisher Scientific Inc. 's 9. 02x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Thermo Fisher Scientific Inc. (TMO) trades at 19. 0x forward P/E versus 28. 6x for Mettler-Toledo International Inc. — 9. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for TMO: 38. 4% to $654. 67.
08Which pays a better dividend — MTD or TMO?
In this comparison, TMO (0.
4% yield) pays a dividend. MTD does not pay a meaningful dividend and should not be held primarily for income.
09Is MTD or TMO better for a retirement portfolio?
For long-horizon retirement investors, Thermo Fisher Scientific Inc.
(TMO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 10), +229. 1% 10Y return). Both have compounded well over 10 years (TMO: +229. 1%, MTD: +271. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between MTD and TMO?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.